Source-grounded facts extracted from BIODESIX INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIODESIX INC shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-05-19 meeting.
“At the Annual Meeting, the stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the vote indicated below:”
BIODESIX INC shareholders approved Non-binding advisory vote on the frequency of solicitation of advisory votes to approve named executive officer compensation at the 2026-05-19 meeting.
“At the Annual Meeting, the stockholders approved, on a non-binding advisory basis, the frequency of solicitation of advisory votes to approve named executive officer compensation by the vote indicated below:”
BIODESIX INC shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2026-05-19 meeting.
“At the Annual Meeting, the stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers by the vote indicated below:”
BIODESIX INC shareholders approved Election of Class III directors at the 2026-05-19 meeting.
“Item 5.07. Submission of Matters to a Vote of Security Holders. Biodesix, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) on May 19, 2026.”
BIODESIX INC reported the first quarter ended March 31, 2026 results: revenue $25.6 million, net income Net loss of $7.8 million. Guidance raised.
“Biodesix Announces First Quarter 2026 Results and Highlights Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million”
BIODESIX INC: Filed a Certificate of Elimination to remove provisions related to Series A Non-Voting Convertible Preferred Stock (effective 2025-09-12).
“On September 12, 2025, Company filed a Certificate of Elimination of the Series A Non-Voting Convertible Preferred Stock (the “Certificate of Elimination”) with the Delaware Secretary of State effecting the elimination of all provisions of the Certificate of Designations previously filed by the Company with the Delaware Secretary of State on April 8, 2024 related to a series of preferred stock designated as Series A Non-Voting Convertible Preferred Stock.”
BIODESIX INC: Effected a one-for-twenty reverse stock split via amendment to the charter (effective 2025-09-15).
“Following such approval, the Company filed an amendment to its Charter (the “Reverse Split Amendment”) with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”) to effect the Reverse Stock Split, with an effective time of 12:01 a.m. Eastern Time on September 15, 2025.”
Charles Watts, M.D. resigned as Director at BIODESIX INC.
“On April 15, 2025, Charles Watts, M.D., a member of the Board of Directors (the “Board”) of Biodesix, Inc. (the “Company”), notified the Company of his intention to resign from his position as a director of the Board and as a member of the Compensation Committee, effective at the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 20, 2025.”
BIODESIX INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“March 24, 2025, Biodesix, Inc. (the “Company”) received written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until September 22”
BIODESIX INC reported the first quarter ended March 31, 2024 results: revenue $14.8 million, net income $13.6 million. Guidance reaffirmed.
“Total revenue of $14.8 million, an increase of 64%”
BIODESIX INC: Filed Certificate of Designations for Series A Non-Voting Convertible Preferred Stock (effective 2024-04-08).
“On April 8, 2024, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “Certificate of Designations”) in connection with the Concurrent Private Placement.”
BIODESIX INC entered into Securities Purchase Agreements with various investors, including certain members of management, certain of its directors and funds affiliated with those directors valued at 760,857 shares of Series A Non-Voting Convertible Preferred Stock at $46.00 per share for aggregate (effective 2024-04-05).
“On April 5, 2024, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with various investors, including certain members of management, certain of its directors and funds affiliated with those directors (the “Investors”) for the issuance and sale by the Company of an aggregate of 760,857 shares of Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) in an offering (the “Concurrent Private Placement”).”
BIODESIX INC entered into Underwriting Agreement with TD Securities (USA) LLC, William Blair & Company, L.L.C., and Canaccord Genuity LLC valued at 17,391,832 shares of Common Stock at $1.15 per share for approximately $18.4 million net proceeds (effective 2024-04-05).
“On April 9, 2024, the Company closed an underwritten offering (the “Offering”) of 17,391,832 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The Common Stock was issued and sold pursuant to an underwriting agreement (the “Underwriting Agreement”), dated April 5, 2024, by and between the Company and TD Securities (USA) LLC, William Blair & Company, L.L.C., and Canaccord Genuity LLC as representatives of the underwriters, at a price to the public of $1.15 per share.”
BIODESIX INC reported the fourth quarter and year ended December 31, 2023 results: revenue $14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively, net income Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively. Guidance reaffirmed.
“Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2023”
BIODESIX INC incurred term loan of $10.0 million with Perceptive Credit Holdings IV, LP at greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. a maturing November 21, 2027.
“On December 15, 2023, the Company exercised its ability to draw the Tranche B loan for $10.0 million (the Tranche B Loan) pursuant to the Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender), executed on November 16, 2022.”
BIODESIX INC reported third quarter ended September 30, 2023 results: revenue $13.5 million, net income $10.9 million. Guidance reaffirmed.
“Total revenue of $13.5 million, an increase of 21%, including COVID testing revenue in third quarter 2022, driven primarily by strong year-over-year growth in lung diagnostics, and a 37% year-over-year increase excluding COVID testing revenues from the prior year comparison;”
BIODESIX INC updated its second quarter ended June 30, 2023 guidance (reaffirmed).
“On August 7, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the second quarter ended June 30, 2023.”
Christopher Vazquez was appointed as Chief Accounting Officer at BIODESIX INC.
“Also effective July 3, 2023, the Company appointed Christopher Vazquez to serve as Chief Accounting Officer.”
Ryan Siurek resigned as Chief Accounting Officer at BIODESIX INC.
“On May 31, 2023, Ryan Siurek informed Biodesix, Inc. (“the Company”) of his resignation as Chief Accounting Officer, effective July 3, 2023.”
BIODESIX INC shareholders approved Approval of the stock option exchange program. at the 2023-05-23 meeting.
“3. At the Annual Meeting, the stockholders approved the stock option exchange program by the vote indicated below: Votes For Votes Against Abstentions Broker Non-Votes 60,434,183 4,164,987 19,570 6,913,414”
BIODESIX INC shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-05-23 meeting.
“2. At the Annual Meeting, the stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the vote indicated below: Votes For Votes Against Abstentions Broker Non-Votes 71,408,435 95,555 28,164 0”
BIODESIX INC shareholders approved Election of three Class III director nominees to serve until the 2026 annual meeting of stockholders. at the 2023-05-23 meeting.
“1. At the Annual Meeting, the Company’s stockholders elected, by the vote indicated below, the following three persons as the Class III directors of the Company, each to serve until the 2026 annual meeting of stockholders and until their respective successors are duly elected and qualify: Name Votes For Votes Against Abstentions Broker Non-Votes Jean Franchi 62,297,395 0 2,321,345 6,913,414 Hany Massarany 61,373,077 0 3,245,663 6,913,414 Jack Schuler 62,235,368 0 2,383,372 6,913,414”
BIODESIX INC reported the first quarter ended March 31, 2023 results: revenue $9.1 million, net income $18.7 million, EPS $0.24. Guidance reaffirmed.
“First Quarter 2023 Financial Results For the three-month period ended March 31, 2023, as compared to the same period of 2022 (where applicable): • Total revenue of $9.1 million, an increase of 38%, driven primarily by strong year-over-year growth in core lung diagnostics: o Core lung diagnostic revenue of $8.6 million reflected a year-over-year increase of 86% driven primarily by the continued adoption of Nodify Lung® nodule management tests; o BioPharma Services revenue of $0.4 million decreased 55% year-over-year. Timelines for existing and new agreements continue to be impacted by delayed enrollment in clinical trials; entered the second quarter of 2023 with continued strong dollars under contract; o COVID-19 testing revenue decreased by 99% year-over-year, and consistent with our revenue guidance. In connection with the expected expiration of the Public Health Emergency declaration, the Company will no longer provide COVID-19 diagnostic testing services commercially; • First quarte”
BIODESIX INC reported fourth quarter and fiscal 2022 results: revenue $9.6 million and $38.2 million, net income Net loss of $20.3 million and $65.4 million. Guidance reaffirmed.
“Total revenue of $9.6 million and $38.2 million for the fourth quarter and fiscal 2022, respectively”
BIODESIX INC updated its the fourth quarter and year ended December 31, 2022 guidance (reaffirmed).
“On March 6, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2022.”
Lawrence (Lair) T. Kennedy was appointed as Director at BIODESIX INC.
“On December 15, 2022, Lawrence (Lair) T. Kennedy was elected and appointed to the Board of Directors of Biodesix, Inc. (the “Company”), with such appointment to be effective and service to commence on January 3, 2023.”
BIODESIX INC incurred term loan of $30.0 million with Perceptive Credit Holdings IV, LP at greater of forward-looking one-month term SOFR and 3.0% per annum, plus an appli maturing November 21, 2027.
“On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender). The Credit Agreement provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $50.0 million (the Perceptive Term Loan Facility). The initial funding of the Perceptive Term Loan Facility was subject to a capital raise of at least $30.0 million in gross proceeds from an equity offering of the Company's common stock.”
BIODESIX INC terminated 2021 Term Loan with Silicon Valley Bank valued at $3 million (effective 2022-11-21).
“and the outstanding principal balance of $3 million under the term loan under the Loan and Security Agreement with Silicon Valley Bank (the 2021 Term Loan)”
BIODESIX INC terminated Promissory Note One with Streeterville Capital, LLC valued at $16.0 million (effective 2022-11-21).
“the Company fully repaid all outstanding principal, accrued and unpaid interest as well as any prepayment and other fees due under the existing $16.0 million promissory note with Streeterville Capital, LLC (Promissory Note One)”
BIODESIX INC entered into Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP valued at up to $50.0 million (effective 2022-11-16).
“On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender).”
BIODESIX INC reported third quarter ended September 30, 2022 results: revenue $11.1 million, net income $(0.34) per diluted share, EPS $(0.34) per diluted share. Guidance reaffirmed.
“College of Chest Physicians (CHEST) annual meeting where we had several key presentations.” Third Quarter 2022 Financial Results For the three-month period ended September 30, 2022, as compared to the same period of 2021 (where applicable): • Total revenue of $11.1 million, an increase of 70%, driven primarily by strong year-over-year growth in core lung diagnostics: o Core lung diagnostic revenue of $9.2 million, reflected a year-over-year increase of 102% driven primarily by the increased adoption of Nodify Lung nodule management tests (Nodify CDT & Nodify XL2 tests) and the recent GeneStrat NGS commercial launch; o COVID-19 testing revenue of $1.3 million reflected a year-over-year increase of 154% that was driven primarily by testing volume under a now expired contract with the State of Colorado; o BioPharma Services revenue of $0.7 million decreased 55% year-over-year.”
Dr. Jon Faiz Kayyem was appointed as director at BIODESIX INC.
“On December 6, 2021, Dr. Jon Faiz Kayyem was appointed to the Board of Directors of Biodesix, Inc. (the “Company”), effective December 6, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.